PDL BioPharma, Inc. (PDLI) Tops Q3 EPS by 1c, Sales Beat Expectations
Tweet
Share
E-mailGet Alerts PDLI Hot Sheet
Join SI Premium – FREE
PDL BioPharma, Inc. (NASDAQ: PDLI) reported Q3 EPS of $0.28, $0.01 better than the analyst estimate of $0.27. Revenue for the quarter came in at $83.8 million versus the consensus estimate of $82.85 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- VNET Group (VNET) Misses Q2 EPS by 164c
- Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
- Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
